Fig. 2.
α+/G301R2 mice display decreased lesion size and improved functional recovery 7 days after SCI. a Functional outcome determined by BMS score in the open field test after SCI was significantly improved in α+/G301R2 compared to α+/+2 mice 7 days after SCI (two-way RM ANOVA: time ****p < 0.0001 F3,42 = 467; genotype *p < 0.05 F1,14 = 8.67; time:genotype **p < 0.01 F3,42 = 6.49, Bonferroni post hoc ****p < 0.0001, n = 7–9 mice/group). b Lesion volume was significantly decreased in α+/G301R2 compared to α+/+2 mice 7 days after SCI when analyzing luxol fast blue (LFB) stained sections (student’s t test, *p < 0.05, n = 6–8 mice/group). c Representative LFB stained thoracic spinal cord sections from α+/+2 and α+/G301R2 mice allowed 7 days survival after SCI. d Lesion volume was significantly decreased in α+/G301R2 compared to α+/+2 mice 7 days after SCI when analyzing GFAP/Nissl/DAPI stainings (student’s t test, *p < 0.05, n = 6–8 mice/group). e Representative GFAP/Nissl/DAPI stained thoracic spinal cord sections from α+/+2 and α+/G301R2 mice allowed 7 days survival after SCI. Results are expressed as mean ± SEM. Scale bar 200 μm